ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir

Publication

ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir

Journal Paper/Review - Apr 1, 2010

Lubomirov Rubin, Telenti Amalio, Csajka Chantal, Decosterd Laurent A, Buclin Thierry, Descombes Patrick, Rentsch Katharina, Ledergerber Bruno, Cavassini Matthias, Calmy Alexandra, Vernazza Pietro, Furrer Hansjakob, Marzolini Catia, Martinez Raquel, Colombo Sara, Fayet Aurélie, di Iulio Julia, Swiss HIV Cohort Study

Citation

Lubomirov R, Telenti A, Csajka C, Decosterd L, Buclin T, Descombes P, Rentsch K, Ledergerber B, Cavassini M, Calmy A, Vernazza P, Furrer H, Marzolini C, Martinez R, Colombo S, Fayet A, di Iulio J, Swiss HIV Cohort Study. ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. Pharmacogenet Genomics 2010; 20:217-30.

Type

Journal Paper/Review (English)

Journal

Pharmacogenet Genomics 2010; 20

Publication Date

Apr 1, 2010

Issn Electronic

1744-6880

Pages

217-30

Brief description/objective

An ADME (absorption, distribution, metabolism and excretion)-pharmacogenetics association study may identify functional variants relevant to the pharmacokinetics of lopinavir co-formulated with ritonavir (LPV/r), a first-line anti-HIV agent.